- Home
- DSGN vs DBL Comparison
DSGN vs DBL Comparison
Compare DSGN & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- DBL
- Stock Information
- Founded
- DSGN 2017
- DBL 2011
- Country
- DSGN United States
- DBL United States
- Employees
- DSGN N/A
- DBL N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- DBL
- Sector
- DSGN Health Care
- DBL
- Exchange
- DSGN Nasdaq
- DBL Nasdaq
- Market Cap
- DSGN 353.9M
- DBL 284.1M
- IPO Year
- DSGN 2021
- DBL N/A
- Fundamental
- Price
- DSGN $6.25
- DBL $15.33
- Analyst Decision
- DSGN Hold
- DBL
- Analyst Count
- DSGN 3
- DBL 0
- Target Price
- DSGN $7.00
- DBL N/A
- AVG Volume (30 Days)
- DSGN 208.4K
- DBL 61.0K
- Earning Date
- DSGN 11-07-2024
- DBL 01-01-0001
- Dividend Yield
- DSGN N/A
- DBL 8.67%
- EPS Growth
- DSGN N/A
- DBL N/A
- EPS
- DSGN N/A
- DBL N/A
- Revenue
- DSGN N/A
- DBL N/A
- Revenue This Year
- DSGN N/A
- DBL N/A
- Revenue Next Year
- DSGN N/A
- DBL N/A
- P/E Ratio
- DSGN N/A
- DBL N/A
- Revenue Growth
- DSGN N/A
- DBL N/A
- 52 Week Low
- DSGN $2.25
- DBL $13.75
- 52 Week High
- DSGN $7.77
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- DSGN 52.38
- DBL 36.15
- Support Level
- DSGN $5.55
- DBL $15.42
- Resistance Level
- DSGN $6.45
- DBL $15.76
- Average True Range (ATR)
- DSGN 0.56
- DBL 0.12
- MACD
- DSGN -0.04
- DBL -0.02
- Stochastic Oscillator
- DSGN 57.67
- DBL 10.20
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.